Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0QTNQH |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | A humanized anti-FOLR1 IgG1 mAb |
|||||
| Antigen Name | FRα |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
ZW191 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligibility: Locally advanced/unresectable or metastatic cancer (measurable per RECIST v1.1), ECOG 0-1, LVEF ≥50%, and adequate organ function. Exclusions: active malignancies requiring treatment, prior TOPO1i ADC therapy, uncontrolled organ dysfunction (renal/liver/pancreatic), or severe active infections (including SARS-CoV-2) needing systemic therapy.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06555744 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors
|
||||
| Primary Endpoint |
Primary safety outcomes (Parts 1-2) include dose-limiting toxicities (DLTs) evaluated within 3 weeks, treatment-related adverse events (AEs), special interest AEs (AESIs), serious AEs (SAEs), and Grade 3+ lab abnormalities per CTCAE v5.0. Key efficacy measures (Part 2) focus on confirmed objective response rate (ORR) by RECIST v1.1 (CR/PR).
|
||||
| Other Endpoint |
Secondary endpoints (Parts 1-2) assess clinical benefit rate (CR/PR/non-CR non-PD/SD lasting ≥180 days), duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), and best overall response (BOR). Pharmacokinetics (serum concentrations & ADA development) will be monitored throughout the study.
|
||||